These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 8754091)
21. Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms. Fidelholtz J; Smith W; Rawls J; Shi Y; Zack A; Rüegg P; Lefkowitz M Am J Gastroenterol; 2002 May; 97(5):1176-81. PubMed ID: 12014724 [TBL] [Abstract][Full Text] [Related]
22. [Treatment of irritable bowel syndrome with dicetelium and spasmomen]. Nedogoda SV; Parshev VV Klin Med (Mosk); 2000; 78(10):42-6. PubMed ID: 11220900 [TBL] [Abstract][Full Text] [Related]
23. New drugs to treat irritable bowel syndrome being tested. Mayo Clin Health Lett; 2000 Mar; 18(3):4. PubMed ID: 10734837 [No Abstract] [Full Text] [Related]
24. A trial of trimebutine in spastic colon. Lüttecke K J Int Med Res; 1978; 6(2):86-8. PubMed ID: 344090 [TBL] [Abstract][Full Text] [Related]
25. Alosetron for irritable bowel syndrome. Senior vice president of GlaxoSmithKline responds. Palmer JB BMJ; 2003 Jan; 326(7379):51. PubMed ID: 12511473 [No Abstract] [Full Text] [Related]
26. Alosetron for irritable bowel syndrome. Risks of using alosetron are still unknown. Palmer RH BMJ; 2003 Jan; 326(7379):51. PubMed ID: 12518769 [No Abstract] [Full Text] [Related]
27. Irritable bowel syndrome. A poorly understood disorder. Lewis C FDA Consum; 2001; 35(4):30-6. PubMed ID: 11692885 [No Abstract] [Full Text] [Related]
28. [Irritable bowel syndrome: current views on its pathogenesis, diagnosis and treatment]. Sheptulin AA Klin Med (Mosk); 1997; 75(9):26-9. PubMed ID: 9432536 [No Abstract] [Full Text] [Related]
30. A clinical trial of trimebutine (Mebutin) in spastic colon. Moshal MG; Herron M J Int Med Res; 1979; 7(3):231-4. PubMed ID: 456734 [TBL] [Abstract][Full Text] [Related]
31. [Comparative study on irritable bowel syndrome treated with acupuncture and western medicine]. Shi ZM; Zhu YS; Wang QX; Lei MN Zhongguo Zhen Jiu; 2011 Jul; 31(7):607-9. PubMed ID: 21823282 [TBL] [Abstract][Full Text] [Related]
32. Delayed reaction urticaria due to trimebutine. Martin-Garcia C; Martinez-Borque N; Martinez-Bohigas D; Torrecillas-Toro M; Palomeque-Rodrìguez MT Allergy; 2004 Jul; 59(7):789-90. PubMed ID: 15180771 [No Abstract] [Full Text] [Related]
33. Tegaserod: a novel, selective 5-HT4 receptor partial agonist for irritable bowel syndrome. Beglinger C Int J Clin Pract; 2002; 56(1):47-51. PubMed ID: 11831835 [TBL] [Abstract][Full Text] [Related]
34. Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects. Morganroth J; Rüegg PC; Dunger-Baldauf C; Appel-Dingemanse S; Bliesath H; Lefkowitz M Am J Gastroenterol; 2002 Sep; 97(9):2321-7. PubMed ID: 12358251 [TBL] [Abstract][Full Text] [Related]
35. A systematic review of tegaserod for the treatment of irritable bowel syndrome. Bergmann K J Clin Pharm Ther; 2003 Apr; 28(2):151-3; author reply 153. PubMed ID: 12713613 [No Abstract] [Full Text] [Related]
36. [Diets in irritable bowel syndrome--what do they really achieve? Please no culinary sadism!]. Stiefelhagen P MMW Fortschr Med; 2001 Nov; 143(46):18. PubMed ID: 11759593 [No Abstract] [Full Text] [Related]